**2018-2020 PRIORITIES CONSULTATION  
*DISCUSSION PAPER***

Table of Contents

[consultation PURPOSE 3](#_Toc518056397)

[Principles for engagement 3](#_Toc518056398)

[CURRENT MRFF STRATEGY AND PRIORITIES 4](#_Toc518056399)

[Table 1: MRFF Strategic Platforms and the 2016-2018 Priorities 5](#_Toc518056400)

[EXISTING MRFF INVESTMENT INITIATIVES 5](#_Toc518056401)

[Table 2: Mapping of committed initiatives to date to the current MRFF Strategy and Priorities 7](#_Toc518056402)

[New Priorities – focus of consultation 8](#_Toc518056403)

[Purpose of the MRFF Priorities 8](#_Toc518056404)

[Scope of the new Priorities 8](#_Toc518056405)

[Consultation Process 9](#_Toc518056406)

[Public Submissions 9](#_Toc518056407)

[Public Forums 10](#_Toc518056408)

[Targeted Roundtable Discussions 10](#_Toc518056409)

[Further Information 11](#_Toc518056410)

[Key Contact 11](#_Toc518056411)

[Staying Informed 11](#_Toc518056412)

[Key References 11](#_Toc518056413)

[Appendix A: Background 12](#_Toc518056414)

[Medical Research Future Fund 12](#_Toc518056415)

[Australian Medical Research Advisory Board 13](#_Toc518056416)

[Appendix B: MRFF Funding Profile 14](#_Toc518056417)

[Table A: MRFF Funding Profile (inflows and outflows) over the first five years 14](#_Toc518056418)

[Table B: MRFF Committed and unallocated funding (as of 30 June 2018) 14](#_Toc518056419)

[Table C: Medical Research Future Fund Measures 14](#_Toc518056420)

[Appendix C: MRFF Initiative Summary and Implementation Status 17](#_Toc518056421)

# consultation PURPOSE

Consistent with the [*Medical Research Future Fund Act 2015*](https://www.legislation.gov.au/Details/C2016C00406) (the Act), the independent Australian Medical Research Advisory Board (AMRAB) is conducting a national consultation to inform the development of the second set of Medical Research Future Fund (MRFF) *Australian Medical Research and Innovation Priorities* (Priorities) for 2018-2020. The timeframe has been chosen to ensure the second set of Priorities can be made prior to when the inaugural MRFF Priorities expire, 8 November 2018.

MRFF Priorities serve to inform future Government decisions on MRFF initiatives and therefore it is important that the community is engaged in their development.

AMRAB is interested in hearing reflections on the first set of MRFF Priorities, the *Australian Medical Research and Innovation Priorities* *2016-2018*, and how the next set of Priorities should extend or reset the direction of the MRFF. Those to be engaged include the Australian public, organisations with expertise in health and medical research and innovation, consumer representatives, clinicians and health services managers. The 2018-2020 Priorities need to be a robust articulation of areas of strategic research investment opportunity informed by the community.

This consultation will commence in July 2018 and will include public forums, targeted themed roundtables and opportunities for public submissions. Details and booking arrangements for the MRFF 2018-2020 Priorities Consultation will be made available on the [MRFF website](http://www.health.gov.au/MRFF). Learnings from the consultation will inform AMRAB’s deliberations on the next set of MRFF Priorities.

## Principles for engagement

In conducting this second MRFF national consultation process, AMRAB has determined the following principles for engagement. Individuals, representatives and organisations are asked to respect these principles in articulating points of view and position statements on the direction of future Priorities.

1. Support for research excellence is paramount, and reference should be given to the [MRFF Funding Principles](http://beta.health.gov.au/resources/publications/medical-research-future-fund-mrff-funding-principles).
2. Appreciate that the MRFF is intended to be transformational - it is a once in a generation opportunity to benefit Australians.
3. Identify potential priorities that represent gaps in knowledge and effort with reference to the following criteria:
   1. Impact – will it make a difference?
   2. Feasibility – can we do it?
   3. Method – is the approach sound?
   4. Value for money – is it worth the investment?
   5. Scientific leadership – are we good at it?
4. Avoid duplication of priorities and effort, and where appropriate identify opportunities to leverage opportunities through collaboration with the purpose of maximising impact.
5. Appreciate the focus on whole-of-system benefit, and stakeholders are encouraged to think beyond single disease or study self-interest.
6. Recognise the importance of priority identification that promotes health and social justice, eliminates discrimination and protects access and equity.
7. Reference the strategic platforms established in the [Australian Medical Research and Innovation Strategy 2016-2021](https://beta.health.gov.au/resources/publications/australian-medical-research-and-innovation-strategy-2016-2021)(the Strategy).
8. Be respectful of other stakeholder perspectives, experiences and opinions.

**IMPORTANT NOTE:** This consultation process is not an opportunity for the submission of funding proposals. MRFF initiatives operate consistent with the [Commonwealth Grants Rules and Guidelines](https://www.finance.gov.au/resource-management/grants/) and aim to align with the Government endorsed [MRFF Funding Principles](http://beta.health.gov.au/resources/publications/medical-research-future-fund-mrff-funding-principles), which means opportunities to submit proposals can only occur within the parameters of designed and advertised, via [GrantConnect](https://www.grants.gov.au/), funding initiatives that include assessment and grant award procedures.

AMRAB recognises that there is a need for greater transparency around priority setting decision making moving forward and intends to use this consultation process to develop new methodologies for priority setting. The Australian Academy of Health and Medical Science is supporting AMRAB in these efforts.

# CURRENT MRFF STRATEGY AND PRIORITIES

The Strategyand[Australian Medical Research and Innovation Priorities 2016-2018](https://beta.health.gov.au/resources/publications/australian-medical-research-and-innovation-priorities-2016-2018)developed by AMRAB were tabled in Parliament consistent with the requirements of the Act on 10 November 2016. Refer to Appendix A for more background.

These documents are the product of extensive consultation led by AMRAB between May and August 2016. Mechanisms used included a call for written submissions, public forums, roundtables, meetings with jurisdictional health departments and a national public webinar. Over 1,000 individuals participated in this consultation process.

AMRAB determined the inaugural MRFF Strategy and Priorities in good faith drawing on the input from the first consultation process.

The inaugural Strategy remains in force and identifies the vision, aim and objectives of the MRFF and the next set of MRFF Priorities must be consistent with this framework:

**VISION:** A health system fully informed by quality health and medical research.

**AIM:** Through strategic investments, to transform health and medical research and innovation to improve lives, build the economy and contribute to health system sustainability.

**OBJECTIVES:**

* Create health and economic benefits from research discoveries and innovations.
* Embed research evidence in healthcare policy and in practice improvement.
* Drive collaboration and innovation across the research pipeline and healthcare system.
* Strengthen transdisciplinary research collaboration.
* Provide better access to research infrastructure.
* Maximise opportunities for research translation by engaging with consumers.
* Position the research sector and health system to tackle future challenges.
* Facilitate the commercialisation of great Australian research.
* Demonstrate the value and impact of research investment.

AMRAB took a deliberate decision in developing the inaugural MRFF Strategy to focus on strategic platforms as opposed to a disease or discipline reference with the intent of ensuring the MRFF was capable of supporting research across the pipeline from discovery to translation and commercialisation. In making this decision, AMRAB noted the need for alignment with the [National Health Priority Areas](https://www.aihw.gov.au/national-health-priority-areas/), evolving burden of disease data, and the [National Indigenous Reform Agreement](http://meteor.aihw.gov.au/content/index.phtml/itemId/668643) to Close the Gap. These points of reference remain highly relevant.

The MRFF Strategic Platforms provided the framework for the inaugural set of MRFF investment priorities for 2016-2018.

### Table 1: MRFF Strategic Platforms and the 2016-2018 Priorities

| **Strategic Platforms** | **2016-2018 Priorities** |
| --- | --- |
| 1. **Strategic and international horizons** | Antimicrobial resistance |
| International collaborative research |
| Disruptive technology |
| 1. **Data and infrastructure** | Clinical quality registries |
| National data management study |
| MRFF infrastructure and evaluation |
| Communicable disease control |
| 1. **Health services and systems** | National Institute of Research |
| Building evidence in primary care |
| Behavioural economics application |
| Drug effectiveness and repurposing |
| 1. **Capacity and collaboration** | National infrastructure sharing scheme |
| Industry exchange fellowships |
| Clinical researcher fellowships |
| 1. **Trials and translation** | Clinical trial network |
| Public good demonstration trials |
| Targeted translation topics |
| 1. **Commercialisation** | Research incubator hubs |
| Biomedical translation |

The current MRFF Priorities will be replaced and refined in November 2018. The focus of this consultation is to inform the second set of Priorities to take effect at the close of the inaugural Priorities.

# EXISTING MRFF INVESTMENT INITIATIVES

The Government has committed $1,717.6 million to date from the MRFF, announced generally in the context of the last two Federal Budgets:

* **2016-17** – $65.9 million over four years and eight initiatives (announced in the context of the 2017-18 Budget);
* **2017-18** - $1,651.7 million over five to 10 years encompassing four extended and 11 new initiatives (announced in the context of the 2018-19 Budget), and grouped in two formats:
  + National Health and Medical Industry Growth Plan – which captures $1.2 billion of MRFF funding; and
  + $510 million across a range of preventive, translation, mission-based and fellowship initiatives.

The Government has articulated the initiatives committed to date according to four themes:

1. **Patients**: Clinical trials with a focus on rare cancers and rare diseases and accelerated research into areas of gaps in research effort.
2. **Researchers**: Clinical research fellowships and industry exchange together with opportunities to establish bold new frontiers in medical science.
3. **Missions**: Brain cancer, mental health and genomics and a concerted effort to transition great ideas through to proof-of-concept and beyond.
4. **Translation**: Preventive, chronic disease, women’s/maternal and early childhood research with a focus on health services research.

Refer to Appendix B for a listing of initiatives and funding profile. A summary of all initiatives, including their status, can be found at Appendix C. Many of the first MRFF initiatives have already been implemented via approach to market calls for applications for grants.

The guidelines and approach to market strategies for those most recently announced initiatives are still under development with announcements of opportunities forthcoming and to be advertised on [GrantConnect](https://www.grants.gov.au/). By registering with GrantConnect, you will be notified about new grants in your area of interest.

The majority (estimated 90 percent) of MRFF initiatives will be provided through either a fully open, or a mixed open and targeted approach to market. This means that only an estimated 10 per cent of initiatives will utilise a targeted approach to grant recipients. AMRAB is keen to ensure that the vast majority of all MRFF funded initiatives are designed and operated consistent with the [MRFF Funding Principles](http://beta.health.gov.au/resources/publications/medical-research-future-fund-mrff-funding-principles)endorsed by the Australian Government.

MRFF initiatives are determined by Government taking into consideration the MRFF Priorities. In developing the initiatives to date the Government took advice from AMRAB to ensure close adherence to the Priorities and relevance to the MRFF Strategy.

Announced MRFF initiatives can be mapped back to the MRFF strategic platforms and 2016‑18 Priorities.

### Table 2: Mapping of committed initiatives to date to the current MRFF Strategy and Priorities

| **Strategic Platforms** | **2016-2018 Priorities** | **MRFF INITIATIVES\*** |
| --- | --- | --- |
| Strategic and international horizons | Antimicrobial resistance | **Tackling Antimicrobial Resistance** |
| International collaborative research | **International Clinical Trial Collaboration** |
| Disruptive technology | **Frontiers in Health and Medical Research**  **Genomics Health Futures Mission** |
| Data and infrastructure | Clinical quality registries | *Captured in part under support for Clinical Trial Activity and Networks.* |
| National data management study | *Associated work will occur under the data and analytics stream of the Genomics Health Futures Mission and ongoing work by the Australian Digital Health Agency.* |
| MRFF infrastructure and evaluation | *Addressed outside of the MRFF with the Government’s commitment of $20 million over four years to support AMRAB activities and program oversight.* |
| Communicable disease control | **Health Security Against Pandemic Risk** |
| Health services and systems | National Institute of Research | - |
| Building evidence in primary care | **Keeping Australians out of Hospital**  **Maternal Health and the first 2,000 Days**  **Targeted Health System and Community Organisation Research** |
| Behavioural economics application | **Boosting Preventive Health Research** |
| Drug effectiveness and repurposing | *Captured in part under the intent of the Australian Brain Cancer Mission and Genomics Health Futures Mission.* |
| Capacity and collaboration | National infrastructure sharing scheme | *Potential reference to Government announcements around the National Research Infrastructure Roadmap.* |
| Industry exchange fellowships | **Industry Researcher Exchange and Training** |
| Clinical researcher fellowships | **Next Generation Clinical Researchers** |
| Trials and translation | Clinical trial network | **Clinical Trial Networks Capacity** |
| Public good demonstration trials | **Clinical Trial Activity** (Lifting Clinical Trial and Registry Capacity and Rare Cancers, Rare Disease and Unmet Need)  **Accelerated Research**  **Australian Brain Cancer Mission**  **Million Minds Mental Health Research Mission** |
| Targeted translation topics | **Rapid Applied Research Translation** |
| Commercialisation | Research incubator hubs | **Biomedical Translation Bridge**  **Targeted Translation Research Accelerator** |
| Biomedical translation | **BioMedTech Horizons** |

*\*NOTE: ‘MRFF Initiatives’ have been organised by primary priority alignment, appreciating that some initiatives address a number of priorities and where relevant this has been notated. Some priorities have been overtaken by policies, programs and agendas outside of the MRFF.*

Subject to consultation, most of the initial MRFF Priorities identified have been or are in the process of being addressed through committed initiatives. Others have been overtaken by policies, programs or agendas operating outside of the MRFF, such as the [National Research Infrastructure Roadmap](https://www.education.gov.au/2016-national-research-infrastructure-roadmap) and the work of the [Australian Digital Health Agency](https://www.digitalhealth.gov.au/). It will be important to revisit the map of initiatives to priorities as part of the consultation process to identify priorities worth retaining, extending and/or refining.

As part of the latest announcements on MRFF funding a number of foundation initiatives are emerging, specifically related to ongoing clinical trials, workforce capacity, early stage research support and research translation. These commitments over a number of years serve to provide predictability with respect to annual approaches to market for grant opportunities. Consultation on the next MRFF Priorities provides an opportunity to inform the future themes within these initiatives to address gaps in capacity and research effort.

# New Priorities – focus of consultation

### Purpose of the MRFF Priorities

As required by the Act, AMRAB is responsible for establishing the Priorities to support the MRFF, with each set of Priorities being in force for two years. The new Priorities 2018-2020 will be the second in the series and will build upon and replace the current Priorities that are in place for 2016‑2018.

The Priorities must be consistent, and align with the vision and strategic platforms that are outlined in the Strategy that is currently in force. Like the Priorities, the MRFF Strategy is developed by AMRAB and informed by national consultation.

The Act requires AMRAB to take into account the following when determining the Priorities:

* the burden of disease on the Australian community;
* how to deliver practical benefits from medical research and medical innovation to as many Australians as possible;
* how to ensure that financial assistance provided under the MRFF complements and enhances other financial assistance provided for medical research and innovation; and
* any other relevant matters.

The MRFF Priorities is a non-disallowable legislative instrument meaning it is tabled in Parliament and are not subject to change, debate or repeal. Once registered in Parliament they are enforced and must be published for public reference.

The Priorities are considered by the Minister for Health before the Commonwealth Government decides on initiatives to fund from the MRFF. For these reasons it is important that the community – patients, clinicians and researchers alike – is engaged in the development of the MRFF Priorities.

### Scope of the new Priorities

The current Priorities for 2016-2018 were purposefully broad to allow for the funding of a variety of new pioneering initiatives through the MRFF. AMRAB was mindful to develop a new ‘top down’ strategic approach to funding that could stimulate health and medical research across the entire research pipeline – from discovery through to translation and commercialisation.

As a number of initiatives have been established, the development of the next set of Priorities provides the opportunity to collectively consider:

1. the appropriateness and effectiveness (to the extent that it is possible to determine at this early stage of initiative implementation) of what has been committed and funded by the MRFF so far;
2. any outstanding Priorities from 2016-2018 that may need to be extended or re‑emphasised;
3. unaddressed gaps in knowledge, capacity and effort across the healthcare continuum and research pipeline;
4. the current status of research capacity, production and use within the health system and how that can be further strengthened through the MRFF;
5. the granularity of Priorities to be determined;
6. the scope of prioritisation with reference to the Strategy - should there be a greater focus on disease burden, threat or opportunity themes;
7. are there any structural priorities that, consistent with the Strategy, should be contemplated;
8. how can the Priorities serve to avoid duplication of effort and leverage co-investment by the private and philanthropic sectors and other existing public programs;
9. are there clinical challenges that Australia is uniquely placed to address;
10. the importance of balance between game-changing endeavours and system improvements;
11. the role the MRFF can play in supporting health and social justice for the vulnerable populations both in Australia and globally; and
12. the changing landscape of health and medical research with the evolution of the digital health, ongoing investment in national research infrastructure and the innovation agenda articulated by [Innovation and Science Australia](https://industry.gov.au/Innovation-and-Science-Australia/Pages/default.aspx).

All Australians – citizens, patients, clinicians and researchers – are welcome to engage in this conversation of which there will be numerous methods by which to do so.

## Consultation Process

AMRAB has determined that the following means will be used to conduct a national consultation on the next set of MRFF Priorities. All details and booking arrangements for the MRFF 2018-2020 Priorities Consultation are available from the [MRFF website](http://www.health.gov.au/MRFF).

### Public Submissions

Online public submissions will open from 29 June 2018 on the Health Department’s Consultation Hub, which can be accessed from the [MRFF website](http://www.health.gov.au/MRFF).

Submissions are to be provided using the online form on the Consultation Hub. Respondents will be asked to identify themselves and if they are affiliated to an organisation. There will be word limits and no allowance for attachments.

Questions for consideration in making a submission include:

1. Are there any outstanding Priorities from 2016-2018 that need to be extended or re-emphasised?
2. What are the unaddressed gaps in knowledge, capacity and effort across the healthcare continuum and research pipeline?
3. What specific priority or initiatives can address any of the above deficits?
4. How can current research capacity, production and use within the health system be further strengthened through the MRFF?
5. Free text commentary with reference to this Discussion Paper.

Those making a public submission are reminded that this is not an opportunity to submit proposals for funding. Rather, the explicit focus of the public submission opportunity is to solicit opinions and perspectives on what AMRAB should consider in determining the next set of MRFF Priorities.

Submissions **will not** be considered if:

* it is a proposal for a grant or a specific request for funding; or
* the submission does not align with the Australian Medical Research and Innovation Strategy 2016–2021, the requirements of the Act, and the MRFF Funding Principles;

Multiple submissions are welcome, however duplicates will not be considered.

Respondents will have an opportunity to indicate consent to have their submission made public on the MRFF website. The decision to post consenting public submissions on the website will be that of AMRAB. All submissions will be reviewed and analysed by the Commonwealth Department of Health’s Office of Health and Medical Research (OHMR) to inform AMRAB’s considerations in developing the second set of MRFF Priorities.

### Public Forums

AMRAB has committed to hold public forums in a number of capital cities during the months of July and August 2018 with further details to be provided on the [MRFF website](http://www.health.gov.au/MRFF). Each forum will be attended by a minimum of three AMRAB members and a supporting team from the OHMR secretariat. The forums will open with a presentation from an AMRAB member and follow with a facilitated discussion between the AMRAB panel and audiences.

### Targeted Roundtable Discussions

A series of targeted roundtables are also being arranged on the following themes:

* consumer-driven research and engagement;
* Indigenous health research;
* aged care research;
* business leader engagement;
* global health and security; and
* research translation and implementation science.

Those attending will include experts in their field of relevance to the topic with an emphasis on ensuring a balanced representation of consumer, clinicians, researchers, funders and healthcare administrators. Invitations will be limited and subject to the decision of AMRAB.

Additional roundtables may be convened at the discretion of AMRAB. Roundtables will be chaired and facilitated by an AMRAB member with support from the OHMR secretariat.

## Further Information

### Key Contact

For any questions relating to this consultation please contact the Department of Health’s OHMR team via [**MRFF@health.gov.au**](mailto:MRFF@health.gov.au).

### Staying Informed

Monitor the [MRFF website](http://www.health.gov.au/MRFF) as it will be regularly updated with events and notifications of opportunities to either engage with AMRAB or reflect on the ongoing national conversation.

### Key References

* [*Australian Medical Research and Innovation Strategy 2016-2021*](https://beta.health.gov.au/resources/publications/australian-medical-research-and-innovation-strategy-2016-2021)https://beta.health.gov.au/resources/publications/australian-medical-research-and-innovation-strategy-2016-2021
* [*Australian Medical Research and Innovation Priorities 2016-2018*](https://beta.health.gov.au/resources/publications/australian-medical-research-and-innovation-priorities-2016-2018)

https://beta.health.gov.au/resources/publications/australian-medical-research-and-innovation-priorities-2016-2018

* [*Medical Research Future Fund Act 2015*](http://www.health.gov.au/MRFF)

https://www.legislation.gov.au/Details/C2016C00406

* [*MRFF Funding Principles*](http://beta.health.gov.au/resources/publications/medical-research-future-fund-mrff-funding-principles)

http://beta.health.gov.au/resources/publications/medical-research-future-fund-mrff-funding-principles

* [AMRAB membership background](https://beta.health.gov.au/committees-and-groups/australian-medical-research-advisory-board-amrab)

https://beta.health.gov.au/committees-and-groups/australian-medical-research-advisory-board-amrab

* [Commonwealth Grants Rules and Guidelines](https://www.finance.gov.au/resource-management/grants/)

https://www.finance.gov.au/resource-management/grants/

* [GrantConnect](https://www.grants.gov.au/)

https://www.grants.gov.au/

* [Business Grants Hub](https://industry.gov.au/smallbusiness/Pages/Business-Grants-Hub.aspx)

https://industry.gov.au/smallbusiness/Pages/Business-Grants-Hub.aspx

* [National Health Priority Areas](https://www.aihw.gov.au/national-health-priority-areas/)

https://www.aihw.gov.au/national-health-priority-areas/

* [National Indigenous Reform Agreement](http://meteor.aihw.gov.au/content/index.phtml/itemId/668643)

http://meteor.aihw.gov.au/content/index.phtml/itemId/668643

* [National Research Infrastructure Roadmap](https://www.education.gov.au/2016-national-research-infrastructure-roadmap)

https://www.education.gov.au/2016-national-research-infrastructure-roadmap

* [Australian Digital Health Agency](https://www.digitalhealth.gov.au/)

https://www.digitalhealth.gov.au/

* [Innovation and Science Australia](https://industry.gov.au/Innovation-and-Science-Australia/Pages/default.aspx)

https://industry.gov.au/Innovation-and-Science-Australia/Pages/default.aspx

## Appendix A: Background

### Medical Research Future Fund

The Medical Research Future Fund (MRFF) is a Commonwealth Government initiative and was announced as part of the 2014‑2015 Budget. The MRFF is the single largest boost to health and medical research funding in Australia’s history. This investment is additional and complementary to the historic and ongoing work of the National Health and Medical Research Council (NHMRC).

The MRFF serves as an ongoing and sustainable endowment fund with a capital target of $20 billion. Annual net earnings are used by Commonwealth Government to help fund health and medical research initiatives. The operating model of the MRFF allows it to employ a strategic and long term approach to funding with a focus on priority investments that address gaps in research and opportunities for research translation and commercialisation.

The MRFF is governed by the *Medical Research Future Fund Act 2015* (the Act),which is the responsibility of the Commonwealth Finance portfolio. The Act outlines how the endowment fund operates under the management of the Future Fund Board of Guardians, and the requirements for the independent Australian Medical Research Advisory Board (AMRAB) to provide guidance to Government on the strategies and priorities to inform decision-making on MRFF funded initiatives.

The Act specifies that the MRFF can only be used to support research and innovation. Recipients of MRFF funding to date have been funded in line with Section 24, which restricts funding to:

* a medical research institute;
* a university;
* a corporate Commonwealth entity; or
* a corporation.

The Act provides flexibility with respect to disbursement mechanisms, noting that they could include existing mechanisms through the National Health and Medical Research Council (NHMRC), corporate institutions or Commonwealth agencies, agreements with jurisdictions, competitive market approaches, or direct source funding.

In administering the MRFF the Department of Health’s OHMR utilises the services of either the NHMRC or the [Business Grants Hub](https://industry.gov.au/smallbusiness/Pages/Business-Grants-Hub.aspx) of the Department of Industry, Innovation and Science consistent with the Government’s Streamlining Grants Administration Policy.

All MRFF funds are directed to research and no MRFF funds are utilised to support grants administration.

All grant opportunities are advertised on [GrantConnect](https://www.grants.gov.au/).

### Australian Medical Research Advisory Board

The Act requires the establishment of an independent advisory board, known as the AMRAB to be appointed by the Minister for Health. AMRAB as an entity needs to collectively possess an appropriate balance of experience and knowledge in the following fields:

* medical research;
* policy relating to health systems;
* management or delivery of health services; medical innovation;
* Financing and investment;
* commercialisation;
* philanthropy; and
* consumer issues relating to health.

AMRAB consists of eight members, including an ex-officio position for the CEO of the NHMRC. The current AMRAB was appointed in April 2016 and members are currently on a five year term. Membership comprises:

* Professor Ian Frazer AC (Chair)
* Professor Doug Hilton AO
* Professor Karen Reynolds
* Professor Peter Høj
* Dr Deborah Rathjen
* Mr Yasser El‑Ansary
* Ms Jennifer Williams AM
* Professor Anne Kelso AO

[AMRAB membership background](https://beta.health.gov.au/committees-and-groups/australian-medical-research-advisory-board-amrab) is available via the MRFF website.

Secretariat support is provided by the Department of Health’s OHMR, which is also responsible for the policy and program oversight of the MRFF.

The Act requires that AMRAB develop a five-yearly Australian Medical Research and Innovation Strategy and every second year an accompanying set of Priorities. In developing these documents, AMRAB is required to consult with community, individuals, representatives and organisations.

The role of AMRAB is to determine a Strategy for the MRFF that ensures there is a coherent and consistent approach adopted to providing financial assistance for health and medical research and innovation. The Priorities provide advice to Government on how to enact the Strategy.

**Importantly, AMRAB is not the decision maker on individual MRFF initiatives.** This role sits with the Government of the day that must, in accordance with the Act, take AMRAB’s prepared Strategy and Priorities into consideration when making decision on how to commit MRFF funding to initiatives.

## Appendix B: MRFF Funding Profile

The Future Fund Board of Guardians is responsible for investing the capital of the MRFF. Credits to the fund are provided by the Commonwealth and the Board of Guardians must work to maintain the nominal value of the credits in order to ensure a predictable and secure ongoing flow of funding for health and medical research and innovation.

It is anticipated that the MRFF will reach full maturity ($20 billion) in 2021 according to the following published modelling from the Department of Finance.

### Table A: MRFF Funding Profile (inflows and outflows) over the first five years

|  |  |  |  |  |  |  |
| --- | --- | --- | --- | --- | --- | --- |
| **MRFF** | **2016-17**  **$m** | **2017-18**  **$m** | **2018-19**  **$m** | **2019-20**  **$m** | **2020-21**  **$m** | **2021-22**  **$m** |
| Credits | 1,277.4 | 2,242.2 | 2,288.6 | 7,830.5 | 2,409.5 | - |
| Disbursements | 60.9 | 121.6 | 214.9 | 386.4 | 642.9 | 646.0 |
| Closing Balance | 4,585.8 | 7,055.7 | 9,471.0 | 17,590.5 | 20,182.1 | 20,418.0 |

*Source: Finance Portfolio Budget Statements 2018-19, page 32.*

Over $6.9 billion has been credited to the MRFF account to date, including the latest credit of $2.2 billion on 22 June 2017.

Over the current forward estimates available disbursements equate to more than $2 billion. Commitments to date by Government total $1,717.6 million, with some decisions extending beyond the current forward estimates to support 10 year initiatives.

### Table B: MRFF Committed and unallocated funding (as of 30 June 2018)

|  |  |  |  |  |  |  |  |  |
| --- | --- | --- | --- | --- | --- | --- | --- | --- |
| **MRFF** | **2016-17**  **$m** | **2017-18**  **$m** | **2018-19**  **$m** | **2019-20**  **$m** | **2020-21**  **$m** | **2021-22**  **$m** | **OUTYEARS**  **$m** | **TOTAL**  **$m** |
| Committed | 18.0 | 143.4 | 222.4 | 317.4 | 357.0 | 222.0 | 437.5 | 1,717.6 |
| Available | 18.0 | 143.4 | 222.4 | 392.7 | 650.2 | 645.9 | N/A | 2,072.5 |
| Unallocated | 0.0 | 0.0 | 0.0 | 75.3 | 293.3 | 423.9 | N/A | 792.4 |

*Note some funding from 2016-17 and 2017-18 has been re-profiled to match outcomes of competitive granting rounds and cash flow requirements for grant recipients.*

This consultation process to develop the next set of MRFF Priorities will inform how the current unallocated funds over the future forward estimates will be committed by Government.

### Table C: Medical Research Future Fund Measures

(Next page)

|  |  |  |  |  |  |  |  |  |  |
| --- | --- | --- | --- | --- | --- | --- | --- | --- | --- |
| **($m)** | **2016-17** | **2017-18** | **2018-19** | **2019-20** | **2020-21** | **2021-22** | **SIX YEAR** | **OUT YEARS** | **TOTAL** |
| **PATIENTS** | | | | | | | | | |
| Clinical Trials Activity: Rare Cancer, Rare Diseases and Unmet need |  | 23.00 | 33.00 | 50.00 | 50.00 | 50.00 | 206.00 |  | 206.00 |
| Accelerated Research | 7.00 | 7.00 | 14.00 | 14.00 | 14.00 |  | 56.00 |  | 56.00 |
| International Clinical Trial Collaboration |  | 4.00 | 6.00 | 8.00 | 12.00 | 12.00 | 42.00 |  | 42.00 |
| Lifting Clinical Trial and Registry Capacity\* |  | 1.95 | 3.64 | 3.51 | 3.90 |  | 13.00 |  | 13.00 |
| Tackling Antimicrobial Resistance\* |  | 2.50 | 1.50 | 1.00 | 0.90 |  | 5.90 |  | 5.90 |
| Clinical Trial Network Capacity | 1.00 | 1.50 | 1.50 | 1.00 |  |  | 5.00 |  | 5.00 |
| National Security Against Pandemic Risk\* |  | 2.00 |  |  |  |  | 2.00 |  | 2.00 |
|  |  |  |  |  |  |  | **329.90** |  | **329.90** |
| **RESEARCHERS** |  |  |  |  |  |  |  |  |  |
| Frontier Health and Medical Research |  | 10.00 | 50.00 | 60.00 | 60.00 | 60.00 | 240.00 |  | 240.00 |
| Next Generation Clinical Researchers\* |  | 11.30 | 12.33 | 21.82 | 22.55 | 10.00 | 78.00 |  | 78.00 |
| Industry Researcher Exchange and Training |  |  | 4.00 | 8.00 | 10.00 | 10.00 | 32.00 |  | 32.00 |
|  |  |  |  |  |  |  | **350.00** |  | **350.00** |
| **MISSIONS** |  |  |  |  |  |  |  |  |  |
| Genomics Health Futures Mission |  | 10.70 | 34.10 | 71.30 | 78.70 | 48.70 | 243.50 | 256.50 | 500.00 |
| Million Minds Mental Health Research Mission |  | 12.50 | 12.50 | 12.50 | 12.50 | 12.50 | 62.50 | 62.50 | 125.00 |
| Brain Cancer Mission |  | 5.00 | 5.00 | 5.00 | 5.00 | 5.00 | 25.00 | 25.00 | 50.00 |
|  |  |  |  |  |  |  | **331.00** | **344.00** | **675.00** |
| **TRANSLATION** |  |  |  |  |  |  |  |  |  |
| Targeted Translation Research Accelerator |  |  |  | 6.50 | 12.50 | 12.50 | 31.50 | 93.50 | 125.00 |
| Rapid Applied Research Translation\* |  | 25.00 | 20.00 | 20.00 | 20.00 |  | 85.00 |  | 85.00 |
| Bio/Med-Tech Horizons\* |  | 10.00 | 5.00 | 10.00 | 20.00 |  | 45.00 |  | 45.00 |
| Targeted Health System & Community Organisation Research |  | 4.80 | 5.00 | 10.00 | 20.00 |  | 39.80 |  | 39.80 |
| Biomedical Translation Bridge |  | 5.10 | 5.30 | 5.30 | 5.30 | 1.30 | 22.30 |  | 22.30 |
| Keeping Australians Out of Hospital |  | 4.50 | 4.50 | 4.50 | 4.60 |  | 18.10 |  | 18.10 |
| Maternal Health and First 2,000 Days |  | 2.50 | 5.00 | 5.00 | 5.00 |  | 17.50 |  | 17.50 |
| Boosting Preventative Health Research | 10.00 |  |  |  |  |  | 10.00 |  | 10.00 |
| ***\* Profiles have been subject to movement of funds since announcement*** | | | | | | | **269.20** | **93.50** | **362.70** |
|  |  |  |  |  |  |  |  |  |  |
|  | **2016-17** | **2017-18** | **2018-19** | **2019-20** | **2020-21** | **2021-22** | **SIX YEAR** | **OUT YEARS** | **TOTAL MRFF** |
| **TOTAL spend** | 18.00 | 143.35 | 222.37 | 317.43 | 356.95 | 222.00 | *1,280.10* | 437.50 | **1,717.60** |
| **TOTAL available MRFF disbursement** | 18.00 | 143.35 | 222.37 | 392.70 | 650.20 | 645.90 | *2,072.52* | N/A |  |
| **Unallocated Funds** | 0.00 | 0.00 | 0.00 | 75.27 | 293.25 | 423.90 | *792.42* | N/A |  |

## Appendix C: MRFF Initiative Summary and Implementation Status

|  |  |
| --- | --- |
|  |  |
| **MRFF Initiative** | **Status** |
| **PATIENTS** | |
| **Clinical Trials Activity: Rare Cancers, Rare Diseases and Unmet Need** – to improve treatments and discover cures for debilitating and deadly rare cancers, rare diseases and areas of unmet need. | **OPEN** |
| **Accelerated Research Investment** - to support emerging priorities and fill gaps in research effort. | **OPEN** |
| **International Clinical Trial collaboration** – toincrease support for international collaboration, enhancing both the skills of researchers and the treatments available to Australian patients. | **UNDER DEVELOPMENT** |
| **Lifting Clinical Trials and Registries Capacity** - to build the capacity of new and existing Clinical Trials Networks and increase and improve treatments for rare cancers, rare diseases and areas of unmet need. | **FUNDED** |
| **Tackling Antimicrobial Resistance** – to better understand the impact patient movement has on AMR in residential aged care facility settings and develop new methods and approaches to prevent, detect and respond to AMR. | **FUNDED** |
| **Clinical Trial Network Capacity -** a national alliance partner to provide highly specialised leadership and support for Clinical Trials Networks to strengthen sector capability and collaboration with the aim of embedding evidence based care in the health system | **FUNDED** |
| **National Security Against Pandemic Risk** – to fund critical research and development gaps for pandemic preparedness and global health security to better protect Australians. | **FUNDED** |
|  |  |
| **RESEARCHERS** |  |
| **Frontier Health and Medical Research** – will provide researchers with the opportunity to develop their bold, ‘blue-sky’ thinking ideas – potentially leading to the next bionic ear, or penicillin. | **UNDER DEVELOPMENT** |
| **Next Generation Clinical Researchers** - to ensure the next generation of talented Australians have the capacity to make and progress great medical discoveries. | **OPEN** |
| **Industry Researcher Exchange and Training** – to foster collaboration between industry and academia with an emphasis on the needs of the end-user (i.e. patients). | **UNDER DEVELOPMENT** |
|  |  |
| **MISSIONS** | |
| **Genomics Health Futures Mission** – will save or transform the lives of 200,000 Australians through new flagship studies, clinical trials, and advancements in technology. | **UNDER DEVELOPMENT** |
| **Million Minds Mental Health Research Mission** – to assist a million people who might otherwise not be part of mental health research and clinical trials to access new approaches to diagnosis, treatment and recovery | **UNDER DEVELOPMENT** |
| **Brain Cancer Mission** - an explicit mission seeking to double brain cancer survival rates and improve quality of life over the next decade, with the longer term aim of defeating brain cancer. | **UNDER DEVELOPMENT** |
|  |  |
| **TRANSLATION** | |
| **Targeted Translation Research Accelerator** – to support early stage research discoveries to reach proof-of-concept and progress to human clinical trials. | **UNDER DEVELOPMENT** |
| **Rapid Applied Research Translation** - to support research that delivers solutions to health service problems that directly benefits patients. | **FUNDED** |
| **BioMedTech Horizons** – to support researchers and entrepreneurs to turn their medical discoveries in viable treatments that will change lives and improve healthcare. | **FUNDED, NEXT OPENNING TBD** |
| **Targeted Health System & Community Organisation Research** – to focus on the comparative effectiveness of health services, address areas of practice with low or insubstantial evidence and provide opportunities for exploring consumer-driven research. | **UNDER DEVELOPMENT** |
| **Biomedical Translation Bridge** – to nurture and progress promising early stage research to successful outcomes. | **UNDER DEVELOPMENT** |
| **Keeping Australians Out of Hospital** - to support preventive health, behavioural economics and implementation science research to reduce avoidable hospitalisations. | **UNDER DEVELOPMENT** |
| **Maternal Health and First 2,000 Days** – to link researchers, institutions, policy makers and professional associations to develop interventions to support a child’s early days of life. | **UNDER DEVELOPMENT** |
| **Boosting Preventative Health Research** – to help promote good health practice, prevent disease and keep people out of hospital | **FUNDED** |